1 Ocak 2021 Konferans bildirisi Açık Erişim

Uslu, Merve; Siyah, Pinar; Harvey, Andrew John; Kocabas, Fatih

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/235844</identifier>
  <creators>
    <creator>
      <creatorName>Uslu, Merve</creatorName>
      <givenName>Merve</givenName>
      <familyName>Uslu</familyName>
    </creator>
    <creator>
      <creatorName>Siyah, Pinar</creatorName>
      <givenName>Pinar</givenName>
      <familyName>Siyah</familyName>
    </creator>
    <creator>
      <creatorName>Harvey, Andrew John</creatorName>
      <givenName>Andrew John</givenName>
      <familyName>Harvey</familyName>
      <affiliation>Yeditepe Univ, Dept Genet &amp; Bioengn, Fac Engn, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Kocabas, Fatih</creatorName>
      <givenName>Fatih</givenName>
      <familyName>Kocabas</familyName>
    </creator>
  </creators>
  <titles>
    <title>Modulating Cas9 Activity For Precision Gene Editing</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2021</publicationYear>
  <dates>
    <date dateType="Issued">2021-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Conference paper</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/235844</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1016/bs.pmbts.2021.01.015</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">The CRISPR/Cas9 is a RNA-guided nuclease complex that can be specifically programmed to target a user-specified DNA sequence. It has been a powerful and effective tool of genome editing. However, off-target activity of the Cas9 nuclease limits its potential use in the correction of inherited diseases and bona fide gene editing. Various protein engineering and guide RNA selection strategies have been utilized to improve Cas9-based genome-editing specificity and efficiency. We, however, have not yet achieved a degree of safety such that Cas9 gene editing approaches could be applicable in clinical settings. Here, we discuss the recently developed and precise gene editing technologies based on spCas9. Furthermore, we describe Cas9 modulating tools to increase the fidelity of the CRISPR/Cas9 system. These studies suggest that there is still a need for pharmaceutical modulation of Cas9 activity during gene editing procedures. Pharmaceutical modulation of Cas9 nuclease activity at on-target or off-target genomic loci could 1 day allow researchers to develop robust and precise therapeutical strategies in gene editing.</description>
  </descriptions>
</resource>